Cardiac hormones, ANP and BNP are considered to be diagnostic markers of CHF, but we need to determine their therapeutic potentials for the treatment and prevention of CVDs such as hypertension, renal insufficiency, cardiac hypertrophy, CHF, and stroke. This evidence concerns the gene NPPB and cardiac hypertrophy.